Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies
JJ Alam, P Maruff, SR Doctrow, HM Chu, J Conway… - Neurology, 2023 - AAN Enterprises
Background and Objectives In a proportion of patients, dementia with Lewy bodies (DLB) is
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
[HTML][HTML] Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
JJ Alam, P Maruff, SR Doctrow, HM Chu, J Conway… - Neurology, 2023 - ncbi.nlm.nih.gov
Methods The AscenD-LB study was a phase 2a, randomized (1: 1), 16-week, placebo-
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
[PDF][PDF] Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
JJ Alam, P Maruff, SR Doctrow, HM Chu, J Conway… - Neurology, 2023 - cervomed.com
Methods The AscenD-LB study was a phase 2a, randomized (1: 1), 16-week, placebo-
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
JJ Alam, P Maruff, SR Doctrow, HM Chu… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background and objectives In a proportion of patients, dementia with Lewy bodies (DLB) is
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
JJ Alam, P Maruff, SR Doctrow, HM Chu, J Conway… - Neurology, 2023 - europepmc.org
Methods The AscenD-LB study was a phase 2a, randomized (1: 1), 16-week, placebo-
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
JJ Alam, P Maruff, SR Doctrow… - …, 2023 - researchinformation.amsterdamumc …
Abstract Background and Objectives In a proportion of patients, dementia with Lewy bodies
(DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
(DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated …
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
JJ Alam, P Maruff, S Doctrow, HM Chu, J Conway… - Neurology, 2023 - europepmc.org
Methods The AscenD-LB study was a phase 2a randomized (1: 1) 16-week placebo-
controlled clinical trial of neflamapimod in DLB, the main results of which have been …
controlled clinical trial of neflamapimod in DLB, the main results of which have been …